GSK2862277 / GSK - LARVOL DELTA

A randomised, placebo-controlled pilot study of a nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury. (PubMed, Eur J Anaesthesiol) - P2 | "Pre-operative treatment with a single 26 mg inhaled dose of GSK2862277 did not result in significantly lower postoperative alveolar capillary leak or extra vascular lung water. Unexpectedly small increases in transpulmonary thermodilution-measured PVPI and extra vascular lung water index at completion of surgery suggest less postoperative lung injury than historically reported, which may have also compromised a clear assessment of efficacy in this trial. GSK2862277 was well tolerated, resulted in expected lung exposure and reduced biomarkers of lung permeability and inflammation."

Clinical • Journal • Immunology • CCL3

A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers (clinicaltrials.gov) - P1; N=54; Completed; Sponsor: GlaxoSmithKline

Clinical • New P1 trial

A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers (clinicaltrials.gov) - P1; N=54; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Clinical • Trial completion